Fierce Biotech reports this morning that Sanofi's Tamaris (NV1FGF) limb ischemia drug couldn't limp its way through a late-stage trial faring no better than the placebo.
Tamaris was supposed to spur growth of new blood vessels in patients who have suffered severe embolism or thrombosis. But the drug failed to show any improvments in preventing amputation or death over 12 months.
The late-stage failure is also bad news for Vical, which provided its non-viral DNA delivery technology to the partnership. The news sent shares of U.S. biotechnology company Vical Inc., which licensed the drug to Sanofi, to a 52-week low during midday trading Wednesday on the Nasdaq Stock Market.
Sanofi takes another hit to its potential revenues and likely will continue its persistent pursuit of Genzyme - no doubt to conclusion - with enhanced vigor.
Posted by Bruce Lehr September 22nd 2010.